Clinical trials: Obese Adult Participants at Risk of Cardiovascular Disease
- Condition Obese Adult Participants at Risk of Cardiovascular Disease
- Funder type Industry (pharma, biotech, devices)
Healthy Subjects (HS), Obese Adult Participants at Risk of Cardiovascular Disease
A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM8969
This is a single center, phase 1, randomized, double-blind, placebo-controlled sequential study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of ISM8969…
- Trial name
- NCT07581431
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- InSilico Medicine Hong Kong Limited
Type 2 Diabetes, Obesity
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk.
- Conditions
- Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight
- Trial name
- ACHIEVE-4 (NCT05803421)
- Testing
- Orforglipron, Insulin Glargine
- Where
- 358 sites in United States, Argentina and 14 more
- Volunteers
- 2,749 people
- Sponsor
- Eli Lilly and Company